Thermo Fisher's Q3 Revenue Climbs, Acquisitions Drive Goodwill Surge

TL;DR

**TMO is betting big on M&A to fuel growth, but watch that rising debt and shrinking cash pile.**

AI Summary

Thermo Fisher Scientific Inc. reported total revenues of $11.12 billion for the three months ended September 27, 2025, an increase from $10.60 billion in the prior year period. Net income attributable to Thermo Fisher Scientific Inc. was $1.62 billion for the quarter, a slight decrease from $1.63 billion in the same period last year. For the nine months ended September 27, 2025, total revenues reached $32.34 billion, up from $31.48 billion, and net income attributable to the company increased to $4.74 billion from $4.51 billion. Key business changes include a significant increase in goodwill to $49.29 billion from $45.85 billion at December 31, 2024, driven by acquisitions totaling $4.04 billion in the nine-month period. Cash and cash equivalents decreased substantially to $1.98 billion from $4.01 billion, primarily due to these acquisition activities and share repurchases of $2.96 billion. The company faces risks related to increased long-term obligations, which rose to $31.86 billion from $29.06 billion, and a decrease in net cash provided by operating activities to $4.36 billion from $5.38 billion. The strategic outlook involves continued M&A activity and managing increased debt levels.

Why It Matters

Thermo Fisher's continued revenue growth and aggressive acquisition strategy, evidenced by $4.04 billion in M&A spending, signal a strong commitment to expanding its market leadership in life sciences and diagnostics. For investors, this indicates potential for long-term value creation through market consolidation, but also highlights increased financial leverage with long-term obligations rising to $31.86 billion. Employees may see new opportunities from integration, while customers could benefit from an expanded product and service portfolio. In a competitive landscape, these strategic moves could further entrench Thermo Fisher's position against rivals like Danaher and Agilent, potentially leading to greater market share and pricing power.

Risk Assessment

Risk Level: medium — The company's risk level is medium due to a significant decrease in cash and cash equivalents from $4.01 billion to $1.98 billion, coupled with a substantial increase in long-term obligations to $31.86 billion from $29.06 billion. Additionally, net cash provided by operating activities decreased to $4.36 billion from $5.38 billion, indicating less internal cash generation to offset increased debt and acquisition spending.

Analyst Insight

Investors should monitor Thermo Fisher's integration of recent acquisitions and their contribution to future earnings. Evaluate the company's ability to generate sufficient free cash flow to service its increased debt load and fund ongoing operations without further eroding its cash reserves. Consider the impact of rising interest rates on its substantial long-term obligations.

Financial Highlights

revenue

$32.34B

operating Margin

16.99%

total Assets

$103.02B

total Debt

$35.68B

net Income

$4.74B

gross Margin

57.7%

cash Position

$1.98B

revenue Growth

+2.7%

Revenue Breakdown

Key Numbers

• $11.12B — Total Revenues (Q3 2025) (Increased from $10.60B in Q3 2024)
• $1.62B — Net Income (Q3 2025) (Slight decrease from $1.63B in Q3 2024)
• $32.34B — Total Revenues (YTD 2025) (Increased from $31.48B in YTD 2024)
• $4.74B — Net Income (YTD 2025) (Increased from $4.51B in YTD 2024)
• $4.04B — Acquisitions (YTD 2025) (Significant increase from $3.13B in YTD 2024)
• $1.98B — Cash & Equivalents (Decreased from $4.01B at Dec 31, 2024)
• $31.86B — Long-term Obligations (Increased from $29.06B at Dec 31, 2024)
• $4.36B — Net Cash from Operations (YTD 2025) (Decreased from $5.38B in YTD 2024)
• $2.96B — Share Repurchases (YTD 2025) (Consistent with $3.00B in YTD 2024)
• $49.29B — Goodwill (Increased from $45.85B at Dec 31, 2024)

Key Players & Entities

• THERMO FISHER SCIENTIFIC INC. (company) — Registrant
• $11.12 billion (dollar_amount) — Total revenues for three months ended September 27, 2025
• $1.62 billion (dollar_amount) — Net income attributable to Thermo Fisher Scientific Inc. for three months ended September 27, 2025
• $32.34 billion (dollar_amount) — Total revenues for nine months ended September 27, 2025
• $4.74 billion (dollar_amount) — Net income attributable to Thermo Fisher Scientific Inc. for nine months ended September 27, 2025
• $4.04 billion (dollar_amount) — Acquisitions, net of cash acquired, for nine months ended September 27, 2025
• $1.98 billion (dollar_amount) — Cash and cash equivalents at September 27, 2025
• $31.86 billion (dollar_amount) — Long-term obligations at September 27, 2025
• $2.96 billion (dollar_amount) — Purchases of company common stock for nine months ended September 27, 2025
• SEC (regulator) — Securities and Exchange Commission

FAQ

Risk Factors

• Increased Debt Levels [medium — financial]: Long-term obligations rose to $31.86 billion from $29.06 billion, increasing financial leverage and interest expense. This rise is linked to significant acquisition activity.
• Acquisition Integration Challenges [medium — operational]: The company has increased goodwill to $49.29 billion due to $4.04 billion in acquisitions year-to-date. Successful integration of these acquisitions is critical for realizing their value and avoiding impairment charges.
• Reduced Cash Position [medium — financial]: Cash and cash equivalents decreased to $1.98 billion from $4.01 billion, primarily due to $4.04 billion in acquisitions and $2.96 billion in share repurchases. This lower cash buffer could limit future flexibility.
• Declining Operating Cash Flow [medium — financial]: Net cash provided by operating activities decreased to $4.36 billion from $5.38 billion year-to-date. This reduction, despite revenue growth, warrants monitoring for potential impacts on liquidity and investment capacity.
• Intense Competition [medium — market]: The life sciences and diagnostics markets are highly competitive, with numerous players offering similar products and services. Maintaining market share and pricing power requires continuous innovation and strategic execution.
• Evolving Regulatory Landscape [low — regulatory]: Changes in healthcare regulations, reimbursement policies, and product approval processes in key markets can impact demand and profitability. Compliance with global regulations is essential.

Industry Context

Thermo Fisher Scientific operates in the highly competitive life sciences and diagnostics industries. Key trends include increasing demand for biopharmaceutical manufacturing services, advancements in genetic sequencing and diagnostics, and a growing focus on personalized medicine. The industry is characterized by significant R&D investment, consolidation through M&A, and evolving regulatory requirements globally.

Regulatory Implications

The company operates under stringent global regulations for pharmaceuticals, medical devices, and laboratory products. Changes in healthcare policies, reimbursement rates, and data privacy laws (like GDPR or HIPAA) can significantly impact revenue streams and operational costs. Compliance with these evolving regulations is a continuous challenge and requires substantial investment.

What Investors Should Do

1. [object Object]
2. [object Object]
3. [object Object]
4. [object Object]

Key Dates

• 2025-09-27: End of Q3 2025 — Reported total revenues of $11.12 billion and net income of $1.62 billion.
• 2025-09-27: End of Nine Months 2025 — Reported total revenues of $32.34 billion and net income of $4.74 billion.
• 2024-12-31: End of Fiscal Year 2024 — Provided the comparative balance sheet figures for goodwill ($45.85B) and cash ($4.01B).

Glossary

Goodwill

An intangible asset that arises when a company acquires another company for a price greater than the fair value of its net identifiable assets. (Significant increase in goodwill ($49.29B) indicates substantial acquisition activity, which is a key strategic driver for Thermo Fisher.)

Acquisition-related intangible assets

Intangible assets such as patents, trademarks, and customer relationships acquired as part of a business acquisition. (These assets, valued at $16.24 billion, represent the value attributed to identifiable intangible assets acquired, separate from goodwill.)

Contract assets, net

Represents the company's right to consideration in exchange for goods or services that the company has transferred to a customer, where that right is conditional on something other than the passage of time. (An increase to $1.62 billion suggests growing long-term contracts or projects with customers.)

Contract liabilities

Represents obligations to transfer goods or services to a customer for which the company has received consideration from the customer. (Stable at $2.85 billion, indicating consistent customer payments received in advance for future services or products.)

Redeemable noncontrolling interest

Represents the portion of equity in a subsidiary that is not attributable to the parent company but has redemption features that could require the parent to buy back the interest. (A small but present liability ($129M), indicating minority ownership stakes in some consolidated entities with redemption rights.)

Treasury stock

Shares of the company's own stock that have been repurchased from the open market. (A significant negative balance ($-22.31B) reflects substantial share repurchase programs, reducing outstanding shares and increasing EPS.)

Year-Over-Year Comparison

Thermo Fisher Scientific reported a modest revenue increase of 2.7% year-to-date to $32.34 billion, compared to $31.48 billion in the prior year. While net income also saw a slight increase to $4.74 billion from $4.51 billion, the company's cash position has significantly weakened, falling to $1.98 billion from $4.01 billion due to aggressive acquisition spending ($4.04 billion YTD) and share repurchases. Concurrently, long-term debt has risen to $31.86 billion from $29.06 billion, and operating cash flow has declined from $5.38 billion to $4.36 billion, indicating increased financial leverage and potential liquidity pressures.

Key Financial Figures

• $1.00 — ange on which registered Common Stock, $1.00 par value TMO New York Stock Exchange

Filing Documents

• tmo-20250927.htm (10-Q) — 2207KB
• q3202510qex311.htm (EX-31.1) — 10KB
• q3202510qex312.htm (EX-31.2) — 10KB
• q3202510qex321.htm (EX-32.1) — 7KB
• q3202510qex322.htm (EX-32.2) — 6KB
• 0000097745-25-000159.txt ( ) — 11150KB
• tmo-20250927.xsd (EX-101.SCH) — 59KB
• tmo-20250927_cal.xml (EX-101.CAL) — 81KB
• tmo-20250927_def.xml (EX-101.DEF) — 306KB
• tmo-20250927_lab.xml (EX-101.LAB) — 755KB
• tmo-20250927_pre.xml (EX-101.PRE) — 518KB
• tmo-20250927_htm.xml (XML) — 2284KB

- FINANCIAL INFORMATION

PART I - FINANCIAL INFORMATION Item 1.

Financial Statements (Unaudited)

Financial Statements (Unaudited) 3 Condensed Consolidated Balance Sheets 3 Condensed Consolidated Statements of Income 4 Condensed Consolidated Statements of Comprehensive Income 5 Condensed Consolidated Statements of Cash Flows 6 Condensed Consolidated Statements of Redeemable Noncontrolling Interest and Equity 7 Notes to Condensed Consolidated Financial Statements 9 Note 1. Nature of Operations and Summary of Significant Accounting Policies 9 Note 2. Supplemental Balance Sheet Information 10 Note 3. Debt and Other Financing Arrangements 11 Note 4. Fair Value Measurements 14 Note 5. Commitments and Contingencies 15 Note 6. Supplemental Income Statement Information 16 Note 7. Income Taxes 18 Note 8. Comprehensive Income/(Loss) and Shareholders' Equity 19 Note 9. Supplemental Cash Flow Information 20 Note 10. Derivatives 20 Note 11. Business Segment Information 21 Note 12. Acquisitions 26 Item 2.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 28 Item 3.

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 36 Item 4.

Controls and Procedures

Controls and Procedures 37

- OTHER INFORMATION

PART II - OTHER INFORMATION Item 1.

Legal Proceedings

Legal Proceedings 37 Item 1A.

Risk Factors

Risk Factors 37 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 37 Item 5. Other Information 37 Item 6. Exhibits 38 2 THERMO FISHER SCIENTIFIC INC.

FINANCIAL INFORMATION

PART I FINANCIAL INFORMATION

Financial Statements

Item 1. Financial Statements CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) September 27, December 31, (In millions except share and per share amounts) 2025 2024 Assets Current assets: Cash and cash equivalents $ 1,982 $ 4,009 Short-term investments 1,564 1,561 Accounts receivable, less allowances of $ 155 and $ 173 8,911 8,191 Inventories 5,745 4,978 Contract assets, net 1,620 1,435 Other current assets 2,472 1,964 Total current assets 22,295 22,137 Property, plant and equipment, net 10,177 9,306 Acquisition-related intangible assets, net 16,242 15,533 Other assets 5,019 4,492 Goodwill 49,287 45,853 Total assets $ 103,020 $ 97,321 Liabilities, redeemable noncontrolling interest and equity Current liabilities: Short-term obligations and current maturities of long-term obligations $ 3,823 $ 2,214 Accounts payable 3,120 3,079 Accrued payroll and employee benefits 1,884 1,988 Contract liabilities 2,852 2,852 Other accrued expenses 3,209 3,199 Total current liabilities 14,888 13,332 Deferred income taxes 842 1,268 Other long-term liabilities 4,278 3,989 Long-term obligations 31,857 29,061 Redeemable noncontrolling interest 129 120 Equity: Thermo Fisher Scientific Inc. shareholders' equity: Preferred stock, $ 100 par value, 50,000 shares authorized; none issued — — Common stock, $ 1 par value, 1,200,000,000 shares authorized; 444,644,993 and 443,841,240 shares issued 445 444 Capital in excess of par value 18,330 17,962 Retained earnings 57,354 53,102 Treasury stock at cost, 68,936,934 and 63,066,906 shares ( 22,310 ) ( 19,226 ) Accumulated other comprehensive income/(loss) ( 2,801 ) ( 2,697 ) Total Thermo Fisher Scientific Inc. shareholders' equity 51,018 49,584 Noncontrolling interests 7 ( 33 ) Total equity 51,024 49,551 Total liabilities, redeemable noncontrolling interest and equity $ 103,020 $ 97,321 The accompanying notes are an integral part of these condensed consolidated financial statements. 3 THERMO FISHE